Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Refractory Macular Edema and Wet AMD
NCT07093385Phase 2Completed
- Sponsor
- College of Medicine, University of Baghdad
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of faricimab in exudative macular degeneration, diabetic macular edema (DME), retinal vein occlusion (RVO), sponsored by College of Medicine, University of Baghdad. Started Sep 2024; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT07093385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093385.